CAPS vs. PCSA, PTEIQ, ASLN, BPTH, CWBR, BPTSY, NMTR, TRVN, EVFM, and APVO
Should you be buying Capstone stock or one of its competitors? The main competitors of Capstone include Processa Pharmaceuticals (PCSA), PolarityTE (PTEIQ), ASLAN Pharmaceuticals (ASLN), Bio-Path (BPTH), CohBar (CWBR), Biophytis (BPTSY), 9 Meters Biopharma (NMTR), Trevena (TRVN), Evofem Biosciences (EVFM), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry.
Capstone vs.
Processa Pharmaceuticals (NASDAQ:PCSA) and Capstone (NASDAQ:CAPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.
Processa Pharmaceuticals has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Capstone has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500.
Processa Pharmaceuticals received 15 more outperform votes than Capstone when rated by MarketBeat users.
Capstone's return on equity of 0.00% beat Processa Pharmaceuticals' return on equity.
In the previous week, Capstone had 5 more articles in the media than Processa Pharmaceuticals. MarketBeat recorded 7 mentions for Capstone and 2 mentions for Processa Pharmaceuticals. Processa Pharmaceuticals' average media sentiment score of 0.44 beat Capstone's score of 0.15 indicating that Processa Pharmaceuticals is being referred to more favorably in the media.
Processa Pharmaceuticals presently has a consensus price target of $6.00, indicating a potential upside of 2,429.51%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Processa Pharmaceuticals is more favorable than Capstone.
Capstone has higher revenue and earnings than Processa Pharmaceuticals.
91.9% of Processa Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.5% of Capstone shares are owned by institutional investors. 13.0% of Processa Pharmaceuticals shares are owned by insiders. Comparatively, 42.8% of Capstone shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Processa Pharmaceuticals beats Capstone on 7 of the 12 factors compared between the two stocks.
Get Capstone News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capstone Competitors List
Related Companies and Tools
This page (NASDAQ:CAPS) was last updated on 4/28/2025 by MarketBeat.com Staff
Buy CAPS Stock Free CAPS Stock Alerts